Logo image
Outcomes After Off-Label Use of the Pipeline Embolization Device for Intracranial Aneurysms: A Multicenter Cohort Study
Journal article   Peer reviewed

Outcomes After Off-Label Use of the Pipeline Embolization Device for Intracranial Aneurysms: A Multicenter Cohort Study

Samer G. Zammar, Thomas J. Buell, Ching-Jen Chen, R. Webster Crowley, Dale Ding, Christoph J. Griessenauer, Brian L. Hoh, Kenneth C. Liu, Christopher S. Ogilvy, Daniel M. Raper, …
World Neurosurgery, Vol.115
2018

Abstract

Adult Aged Cohort Studies Embolization, Therapeutic Female Follow-Up Studies Humans Intracranial Aneurysm Male Middle Aged Off-Label Use Prospective Studies Retrospective Studies Treatment Outcome abciximab adult aneurysm rupture angiography Article clinical outcome cohort analysis female follow up human intracranial aneurysm major clinical study male multicenter study off label drug use postoperative period Rankin scale retrospective study risk benefit analysis aged artificial embolization clinical trial devices diagnostic imaging intracranial aneurysm middle aged prospective study treatment outcome trends
Objective: To examine outcomes of Pipeline embolization device (PED) use for treatment of intracranial aneurysms outside of U.S. Food and Drug Administration–approved indications. Methods: Data from patients with aneurysms treated with off-label use of PED were pooled from 4 centers in a retrospective multicenter cohort study. Primary endpoints were decline in modified Rankin Scale score by at least 1 point and angiographic aneurysm occlusion at follow-up. Results: The study cohort comprised 109 patients. Mean aneurysm size was 8.4 ± 7.4 mm, 20.2% of aneurysms were located in the posterior circulation, and 11.9% of aneurysms were ruptured. The most common reasons for off-label use were aneurysm size (50.5%), aneurysm location (25.7%), and both size and location (10.1%). Mean follow-up was 9 months. Complete occlusion was achieved in 82.5% of cases at last angiographic follow-up. Modified Rankin Scale score decline was found in 18.8% of cases. On univariate analysis, age, aneurysm size, aneurysm morphology, aneurysm location, reason for off-label use, and rupture status were not associated with clinical decline or aneurysm occlusion on angiography. On multivariate analysis, treatment of a ruptured aneurysm with PED was found to be an independent predictor of postoperative decline in modified Rankin Scale score, and size as the only reason for off-label PED use was found to be an independent predictor of complete occlusion on final angiography. Conclusions: Off-label use of PED has a reasonable risk-to-benefit profile for appropriately selected aneurysms. Posterior circulation location and fusiform morphology do not appear to be associated with worse clinical or angiographic outcomes. © 2018 Elsevier Inc.

Metrics

6 Record Views

Details

Logo image